EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

SAP (SAP GR) Germany

Technology

AIR Capital

SAP is guiding for cloud revenues to reach €14.1bn (+25% Y/Y) in FY23, suggesting growth will be far stronger in H2 vs. H1, in total contradiction with the current economic slowdown and competitors’ recent comments. Pierre-Olivier Essig struggles to share management’s bullishness which has led to him downgrading the stock to Sell (from Buy). His new TP is €100 (previously €140).

AIR continues to boast an enviable track record with impressive gains on Buy-rated stocks including Aixtron, Meier Tobler, Novo Nordisk and Rolls-Royce, as well as shorts including Fresenius Medical Care and Grifols.

Edition: 171

- 13 October, 2023


Fresenius SE (FRE GR) & Fresenius Medical (FME GR) Germany

Healthcare

CTFN

Elliott has taken a stake in Fresenius SE, but the company’s top shareholder, the Else Kroner Foundation, is an obstacle to immediate value creation, a source told CTFN. As Elliott faces down the foundation, the activist could force a breakup of Fresenius Medical, a partially owned subsidiary of the company, or agitate for equity-dilutive M&A by subsidiary Kabi to improve its market share in the US. Bankers are already pitching the firm’s components to potential private-equity bidders, with subsidiary Vamed proving the toughest sell, the source said. Click here for the full story.

Edition: 148

- 11 November, 2022